Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women

Menopause

Volumn 9, Issue 2, 2002, Pages 137-144

  Brynhildsen, Jan ^a   Hammar, Mats ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amenorrhea; Continuous combined; Estradiol; Low dose; Norethisterone acetate; Transdermal HRT

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AMENORRHEA; ARTICLE; BLEEDING; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; FRACTURE; HUMAN; HUMAN TISSUE; INCIDENCE; MORPHOLOGY; MULTICENTER STUDY; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; THICKNESS; THORAX PAIN; UTERUS BLEEDING;

EID: 0036188062     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200203000-00009     Document Type: Article

References (33)

1. Hormonal treatment for the climacteric: Alleviation of symptoms and prevention of post-menopausal disease
2. Breast cancer and hormonal replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
3. Risks of breast cancer and endometrial cancer after estrogen and estrogen-progestin replacement
4. Extraskeletal effects of estrogen and the prevention of atherosclerosis
5. Hormone therapy to prevent disease and prolong life in postmenopausal women
6. The menopause, hormone replacement and cardiovascular disease: The epidemiologic evidence
7. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
8. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
9. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens
10. Transdermal estradiol overall safety profile
11. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women
12. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: Effects on the endometrium
13. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: Vasomotor symptoms, bleeding patterns, and serum lipids
14. Risk of endometrial cancer following estrogen replacement with and without progestins
15. Continuous combined hormone replacement therapy and risks of endometrial cancer
16. Estrogen replacement in postmenopausal women: Are we currently overdosing our patients?
17. Transdermal estradiol: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of menopausal complaints
18. Pharmacokinetics and pharmacodynamics of transdermal forms of 17β-estradiol: Comparison with conventional oral estrogens used for hormone replacement
19. Efficacy and local tolerance of a low dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms
20. 17β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy
21. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
22. Endometrial morphology in asymptomatic postmenopausal women
23. Hormone replacement therapy in postmenopausal women: Endometrial hyperplasia and irregular bleeding (Cochrane review)
24. Risk of endometrial cancer following estrogen replacement with and without progestins
25. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study)
26. Accumulated knowledge of Kliogest safety aspects
27. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions trial
28. Evaluation of a continuous combined low-dose regimen of estrogen progestin for treatment of the menopausal patient
29. Compliance with hormonal replacement therapy
30. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints
31. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
32. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies